Pfizer Inc. (NYSE:PFE) Shares Acquired by First Bank & Trust

First Bank & Trust increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 77,695 shares of the biopharmaceutical company’s stock after buying an additional 2,459 shares during the quarter. First Bank & Trust’s holdings in Pfizer were worth $2,248,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Olistico Wealth LLC purchased a new stake in Pfizer during the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer in the second quarter valued at approximately $29,000. Quarry LP acquired a new stake in Pfizer during the second quarter worth approximately $31,000. Trivant Custom Portfolio Group LLC grew its stake in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the period. Finally, Financial Connections Group Inc. acquired a new position in Pfizer in the 2nd quarter valued at $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on PFE. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Wells Fargo & Company lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday. Finally, Citigroup started coverage on Pfizer in a report on Friday. They issued a “neutral” rating and a $30.00 price target for the company. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Stock Down 0.7 %

Shares of PFE stock traded down $0.19 during trading hours on Friday, hitting $28.45. 26,091,111 shares of the company were exchanged, compared to its average volume of 36,849,277. The business’s 50-day simple moving average is $29.08 and its two-hundred day simple moving average is $28.50. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The stock has a market capitalization of $161.22 billion, a price-to-earnings ratio of -61.85, a P/E/G ratio of 1.01 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period in the previous year, the business posted $0.67 EPS. The company’s quarterly revenue was up 2.1% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.67 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.91%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is -365.21%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.